New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
Castle Biosciences announced publication of a decision modeling study in the Annals of Gastroenterology showing its TissueCypher Barrett's Esophagus test significantly improves risk-aligned management across non-dysplastic, indefinite, and low-grade dysplasia BE patients. Across 699 pooled patients, adding TissueCypher to clinical decision-making raised appropriate management from 59.8% to 75.3%, and in non-dysplastic BE patients who later progressed to high-grade dysplasia or cancer, appropriate escalation nearly doubled from 30.4% to 56.9%. Among all non-progressors, the model projected a 41.7% reduction in overtreatment.
Key figures
- Drug Name
- TissueCypher Barrett's Esophagus test (TSP-9)
- Pooled patients
- 699
- Validation studies
- 5
- Overtreatment reduction
- 41.7%
- Undertreatment reduction
- 31.9%
- Peer reviewed publications
- more than 17
- Cumulative patients studied
- more than 8,000
- Progressor escalation change
- 50.5% to 66.3% (P=0.008)
- Appropriate management change
- 59.8% to 75.3% (P<0.001)
- Ndebe progressor escalation change
- 30.4% to 56.9% (P=0.001)
- Ndebe share of us surveillance patients
- approximately 89%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.